Advertisement

Glutamate and Addiction

  • Barbara H. Herman
  • Jerry Frankenheim
  • Raye Z. Litten
  • Philip H. Sheridan
  • Forrest F. Weight
  • Steven R. Zukin

Part of the Contemporary Clinical Neuroscience book series (CCNE)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. Karin Borges, Raymond Dingledine
      Pages 3-21
    3. Jeffrey M. Witkin, Rafal Kaminski, Michael A. Rogawski
      Pages 23-49
    4. B. Joy Snider, Dennis W. Choi
      Pages 51-61
  3. Glutamate

    1. Front Matter
      Pages 81-81
    2. Marina E. Wolf
      Pages 127-141
    3. David A. Baker, Jennifer L. Cornish, Peter W. Kalivas
      Pages 143-156
    4. Kristan B. Burrows, Bryan K. Yamamoto
      Pages 211-227
    5. Yossef Itzhak, Julio L. Martin, Syed F. Ali
      Pages 229-242
  4. Glutamate and Opiate Drugs (Heroin) of Abuse

  5. Glutamate and Alcohol Abuse and Alcoholism

    1. Front Matter
      Pages 341-341
    2. Robert W. Peoples
      Pages 343-356
    3. Fulton T. Crews, Joseph G. Rudolph, L. Judson Chandler
      Pages 357-373
    4. Howard C. Becker, Nicole Redmond
      Pages 375-387
    5. John H. Krystal, Ismene L. Petrakis, D. Cyril D’Souza, Graeme Mason, Louis Trevisan
      Pages 389-397
    6. W. Zieglgänsberger, G. Rammes, R. Spanagel, W. Danysz, Ch. Parsons
      Pages 399-407
    7. Gavril W. Pasternak, Yuri Kolesnikov
      Pages 409-416
    8. Adriaan S. Potgieter
      Pages 417-426
  6. Back Matter
    Pages 427-440

About this book

Introduction

The past decade has witnessed a growing body of preclinical and clinical evidence that glutamatergic systems may play a pivotal role in drug dependence. In Glutamate and Addiction, world-renowned scientific experts critically review all of this evidence and make the case for the role of glutamatergic systems in both the etiology and treatment of addiction disorders. The authors examine the glutamate connection in stimulant drugs of abuse (cocaine, amphetamine, and methamphetamine), in opiate addiction, and in alcohol abuse and dependence. Using a variety of pharmacological, biochemical, genetic, and brain imaging techniques, these investigators show precisely how glutamate is involved in the etiology of addictions and how blocking or activating certain elements of the glutamatergic system appear to alleviate particular components of addiction. Their survey takes in both clinical approaches using medications that influence glutamate and cutting-edge preclinical approaches that manipulate specific subtypes of glutamate receptors or specific substrates of the "glutamate cascade" to determine their roles in various addictive states. The discussion includes a full review of possible treatments of addiction using glutamatergic antagonists and co-agonists such as acamprosate to modify specific aspects of glutamate function in the central nervous system.
Illuminating, authoritative, and forward looking, Glutamate and Addiction clarifies for the first time the relationship between glutamatergic systems and addiction and sets the stage for productive experimental and clinical investigations of many of today's emerging therapeutics for addictive disorders.

Keywords

Opioid amphetamine cocaine dopamine drugs of abuse imaging techniques neurotoxicity physiology

Editors and affiliations

  • Barbara H. Herman
    • 1
  • Jerry Frankenheim
    • 2
  • Raye Z. Litten
    • 3
  • Philip H. Sheridan
    • 4
  • Forrest F. Weight
    • 5
  • Steven R. Zukin
    • 6
  1. 1.Clinical Medical Branch, Division of Treatment Research and DevelopmentNational Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)BethesdaUSA
  2. 2.Pharmacology, Integrative & Cellular Neurobiology Research Branch (PICNRB), Division of Neuroscience & Behavioral Research (DNBR)National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)BethesdaUSA
  3. 3.Treatment Research Branch, Division of Clinical and Prevention ResearchNational Institute on Drug Abuse (NIAAA), National Institutes of Health (NIH)BethesdaUSA
  4. 4.Division of Neuropharmacological Drug Products Center for Drug Evaluation and ResearchOffice of Drug Evaluation I, Food and Drug AdministrationRockvilleUSA
  5. 5.Laboratory of Molecular and Cellular Neurobiology, Division of Intramural Clinical and Biological ResearchNational Institute on Drug Abuse (NIAAA) National Institutes of Health (NIH)BethesdaUSA
  6. 6.Division of Treatment Research and DevelopmentNational Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)BethesdaUSA

Bibliographic information